Peter Goodwin speaks to Professor Robert Coleman about targeted therapy, specifically treatment that targets bone metastases. Prof Coleman explains how metastases move to the bone in many cancers and talks about cancer cells lying dormant in bone marrow. Prof Coleman explains the effects denosumab, zoledronic acid and other bisphosphonates have on incidence of skeletal related events and survival rates and talks about a study comparing denosumab with zoledronic acid as treatment for prostate cancer and bone metastases.